Trial · NCT00887250
A Study to Investigate the Antihypertensive Efficacy of MK0954
NCT00887250, Phase 3, Completed, Merck Sharp & Dohme LLC; results first posted 2009-06-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Investigate the Antihypertensive Efficacy of MK0954. Trials, record NCT00887250. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00887250
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Investigate the Antihypertensive Efficacy of MK0954
- NCT number
- NCT00887250
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 366 participants, actual
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Hypertension
- Interventions
- losartan potassium, Comparator: losartan, Comparator: Placebo
- First posted
- 2009-04-23
- Last updated
- 2009-07-14
- Results first posted
- 2009-06-24
- Limitations and caveats
- Safety has been reported in the literature.
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | At baseline and at 12 weeks (24 hours post dose) | Mean change from baseline in trough (24 hours post dose) SiDBP at Week 12 |
| Secondary | Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6 | 24 hours post dose at Week 6 | Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III. |
| Secondary | Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12 | 24 hours post dose at Week 12 | Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III. |
| Secondary | Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6 | At baseline and at 6 weeks (24 hours post dose) | Mean change from baseline in trough (24 hours post dose) SiDBP at Week 6 |
| Secondary | Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6 | At baseline and at 6 weeks (24 hours post dose) | Mean change from baseline in peak (6 hours post dose) SiDBP at Week 6 |
| Secondary | Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | At baseline and at 12 weeks (6 hours post dose) | Mean change from baseline in peak (6 hours post dose) SiDBP at Week 12 |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | At baseline and at 12 weeks (24 hours post dose) | The primary analysis employed an all patients treated approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available. | mm Hg | MEAN |
| SECONDARY | Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6 | 24 hours post dose at Week 6 | An all patients treated approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available. | Participants | NUMBER |
| SECONDARY | Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12 | 24 hours post dose at Week 12 | An all patients treated approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available. | Participants | NUMBER |
| SECONDARY | Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6 | At baseline and at 6 weeks (24 hours post dose) | An all patients treated approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available. | mm Hg | MEAN |
| SECONDARY | Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6 | At baseline and at 6 weeks (24 hours post dose) | The primary analysis employed an all patients treated approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available. | mm Hg | MEAN |
| SECONDARY | Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | At baseline and at 12 weeks (6 hours post dose) | The primary analysis employed an all patients treated approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available. | mm Hg | MEAN |
Source ClinicalTrials.gov
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | Placebo | -4.3 | Standard Deviation 6.7 | mm Hg | |
| Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | Losartan 50 mg | -7.9 | Standard Deviation 7.6 | mm Hg | |
| Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | Losartan 50/100 mg | -8.6 | Standard Deviation 7.7 | mm Hg | |
| Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6 | Placebo | Category I | 14 | Participants | |
| Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6 | Losartan 50 mg | Category I | 37 | Participants | |
| Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6 | Losartan 50/100 mg | Category I | 37 | Participants | |
| Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6 | Placebo | Category II | 8 | Participants | |
| Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6 | Losartan 50 mg | Category II | 20 | Participants | |
| Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6 | Losartan 50/100 mg | Category II | 21 | Participants | |
| Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6 | Placebo | Category III | 92 | Participants |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 116 | |
| Overall Study | STARTED | Losartan 50 mg | 127 | |
| Overall Study | STARTED | Losartan 50/100 mg | 123 | |
| Overall Study | COMPLETED | Placebo | 98 | |
| Overall Study | COMPLETED | Losartan 50 mg | 115 | |
| Overall Study | COMPLETED | Losartan 50/100 mg | 110 | |
| Overall Study | NOT COMPLETED | Placebo | 18 | |
| Overall Study | NOT COMPLETED | Losartan 50 mg | 12 | |
| Overall Study | NOT COMPLETED | Losartan 50/100 mg | 13 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00887250
GET https://conductscience.org/api/trials/v1/NCT00887250/results?page=2